Enable JavaScript to visit this website.


Help reduce the risk of MenB

You have taken a first step to help protect yourself against MenB, an uncommon but potentially deadly disease.1,2

Now it is important to complete the TRUMENBA vaccination series.

Enroll in the REMEMBER TRUMENBA Program and receive text reminders to help you stay on track.


Please provide the information requested below to receive useful reminders on when you should schedule your upcoming vaccination.

*Required Field.

I would like to enroll in the REMEMBER TRUMENBA Program and receive dosing reminders*:

To ensure that the messages are provided according to the appropriate dosing schedule, please provide the date of your first vaccination and choose the dosing schedule recommended by your health care provider or pharmacist*:

Mobile Terms and Conditions: By checking the box for text messages, you agree to receive autodialed text messages from or on behalf of Pfizer at the telephone number(s) that you provide. You understand that this is not a condition of purchase or use of TRUMENBA or of any Pfizer product or service.

  • There is no fee payable to Pfizer to receive text messages; however, your carrier’s message and data rates may apply
  • Data obtained from you in connection with your registration for, and use of, this SMS service may include your phone number, related carrier information, and elements of pharmacy claim information and will be used to administer this program and to provide program benefits such as dosing reminders, program updates and alerts
  • Pfizer will not be liable for any delays in the receipt of any SMS messages as delivery is subject to effective transmission from your network operator. T-Mobile is NOT liable for delayed or undelivered messages.
  • Pfizer reserves the right to rescind, revoke, or amend the REMEMBER TRUMENBA Program without notice at any time
  • You may receive up to 10 messages a month. Pfizer’s privacy policy is available at www.pfizer.com/general/privacy. You may unsubscribe from the Program at any time by texting STOP to 37500. For help, text HELP.

Pfizer understands that your personal and health information are private. The information you provide will only be used by Pfizer and parties acting on its behalf to send you the materials you requested and other helpful information and updates on TRUMENBA, as well as related treatment, products, offers, and services.

  1. Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397-403.
  2. Soeters HM, McNamara LA, Whaley M, et al. Serogroup B meningococcal disease outbreak and carriage evaluation at a college—Rhode Island, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(22):606-607.
pharmacy icon

Want to know where you can get TRUMENBA near you?

Find a location
locator icon
Already received the first dose of TRUMENBA?

Get text reminders for the next dose.

Enroll now
  • Trumenba should not be given to anyone with a history of a severe allergic reaction after a previous dose of Trumenba
  • Some individuals with weakened immune systems may have a reduced immune response
  • Persons with certain complement deficiencies and persons receiving treatments such as Soliris® (eculizumab), are at increased risk for invasive disease caused by Neisseria meningitidis group B even with receipt of vaccination with Trumenba
  • As with any vaccine, vaccination with Trumenba may not protect all vaccine recipients against N meningitidis group B infections
  • Fainting can occur in association with administration of injectable vaccines, including Trumenba
  • The most common adverse reactions in adolescents and young adults were pain at injection site, fatigue, headache, and muscle pain. Nausea was reported in adolescents in early phase studies
  • Data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
  • Tell your health care provider if you are pregnant, or plan to become pregnant
  • Ask your health care provider about the risks and benefits of Trumenba. Only a health care provider can decide if Trumenba is right for you or your child
  • Trumenba is a vaccine indicated for individuals 10 through 25 years of age for active immunization to prevent invasive disease caused by Neisseria meningitidis group B
  • The effectiveness of the two-dose schedule of Trumenba against diverse N meningitidis group B strains has not been confirmed
Call 1-844-TRUMENBA (878-6362), 9 AM to 7 PM ET, Monday through Friday, for more information.

Patients should always ask their doctors for medical advice about adverse events.

You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967.

This product information provided in this site is intended only for residents of the United States. The products discussed in this site may have different product labeling in different countries.

The health information in this site is provided for educational purposes only and is not intended to replace discussions with a health care provider. All decisions regarding patient care must be made with a health care provider, considering the unique characteristics of the patient.

Back to top